Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18989462 | 0.92 | APLNR (0.54) | APLNR | |
| SCHEMBL20584451 | 0.89 | APLNR (0.54) | APLNR | |
| SCHEMBL20584718 | 0.88 | APLNR (0.60) | APLNR | |
| SCHEMBL19001438 | 0.87 | APLNR (0.39) | APLNR | |
| SCHEMBL20584753 | 0.87 | APLNR (0.51) | APLNR | |
| SCHEMBL19001460 | 0.85 | APLNR (0.40) | APLNR | |
| SCHEMBL22912191 | 0.85 | APLNR (0.41) | APLNR | |
| SCHEMBL18990730 | 0.85 | APLNR (0.60) | APLNR | |
| SCHEMBL20584790 | 0.85 | APLNR (0.49) | APLNR | |
| SCHEMBL20584786 | 0.84 | APLNR (0.49) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602813-B | Heteroaryl hydroxypyrimidinones as APJ receptor agonists | 百时美施贵宝公司 | 2021-10-29 | — | — | CN | claimed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | claimed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | claimed |
| CN-108602813-B | Heteroaryl hydroxypyrimidinones as APJ receptor agonists | 百时美施贵宝公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-3390400-B1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2021-01-20 | — | — | EP | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | Bristl-Myers Squibb Company (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180362508-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2018-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669261-B2 | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | APLNR, GPBAR1, AGTR1 | APLNR 1/4885 |
| US-20180362508-A1 | HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR | APLNR, GPBAR1, AGTR1 | APLNR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.